Plasma Asprosin Concentrations are Associated with Progression of Diabetic Kidney Disease
DOI: https://doi.org/10.2147/dmso.s447465
2024-06-05
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Mingyue Xu, &ast Chunlin Zhang, &ast Linlin Zhang, Hua Qu, Yuren Wang Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, Second Affiliated Hospital of Army Medical University, Chongqing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hua Qu; Yuren Wang, Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, the Second Affiliated Hospital of Army Medical University, Chongqing, 400037, People's Republic of China, Tel +86 2368763255, Fax +86 2368755707, Email ; Purpose: To explore the expression of asprosin in subjects with pre-DKD and DKD and to analyze its relationship with kidney injury, inflammation, and glucose and lipid metabolism. Methods: Based on urine albumin:creatinine ratio (UACr), participants were divided into DM, pre-DKD, and DKD groups. Relevant human physiological and biochemical parameters were detected in the three groups. Results: We found relatively higher levels of asprosin in both pre-DKD and DKD groups than the DM group. Moreover, data from the Nephroseq database support increased gene expression of asprosin in kidney tissue from DKD patients. Further correlation analysis revealed that the plasma asprosin level was positively correlated with age, waist circumference, waist:hip ratio, systolic blood pressure, creatinine, UACr, triglycerides, HDL-c, fasting insulin, HOMA-IR, and the inflammatory marker G3P and negatively associated with eGFR. Multiple logistical regression analysis showed that asprosin concentration was significantly associated with pre-DKD and DKD after adjusting for sex, age, BMI, WHR, and HOMA-IR, while this correlation was lost after controlling for G3P. Conclusion: Plasma asprosin is associated with kidney injury in diabetic conditions, and this association might be connected through inflammatory response. Further studies are needed to assess the role and mechanism of asprosin in DKD. Keywords: asprosin, diabetes, diabetic kidney disease, kidney injury With the increasing prevalence of diabetes worldwide, the incidence of chronic complications of diabetes, such as diabetic retinopathy, diabetic kidney disease (DKD), and diabetic neuropathy, is also rising. 1 Among these, DKD has become the leading cause of end-stage renal disease in developed countries, 2,3 and its incidence in type 1 and type 2 diabetes isas high as 30% and 40%, respectively. 1,4 Therefore, understanding the risk factors related to the progression of DKD is critical in the treatment and prevention of DKD. In previous studies, the increased level of circulating glucose was thought to be the pathogeny of kidney injury under diabetic situations. 5 However, several large-scale clinical trials (ACCORD, VADT, ADVANCE) failed to find a positive outcome after intensive control of glucose. 6 In recent years, adipokines, which are predominantly secreted from adipose tissue, were found to regulate functions of other organs, and were reported to participate in the pathology of DKD via inflammatory response. 7 Asprosin is such a sample. It is a C-terminal cleavage product of profibrillin (FBN1) secreted by white adipocytes, and was found to regulate the gluconeogenesis process in the liver. 8 Our previous studies have shown that plasma asprosin is increased in patients with type 2 diabetes and insulin resistance. 9 Moreover, it also has been reported to be associated with several inflammatory parameters, such as IL6 and MCP1. 10,11 Considering the double roles of asprosin in glucose metabolism and inflammation, we suspected that it may take part in the pathological processes of DKD. To answer this question, we conducted a cross-sectional study to evaluate plasma levels of asprosin in DM, pre-DKD, and DKD populations and to analyze their correlations with kidney function and injury. Our study recruited a total of 82 subjects. They were divided into three groups in based on urine albumin:creatinine (Cr) ratio (UACr): diabetic subjects without kidney disease (DM, n=22), early-stage DKD (pre-DKD, n=20), and DKD (n=40). Inclusion criteria were age >18 years, diabetes diagnosed on the basis of diagnostic criteria of the WHO (1999), and with pre-DKD (UACr ≥30 but <300 mg/g or DKD (UACr) ≥300 mg/g. Exclusion criteria were history of smoking and drinking, acute complications of DM, such as diabetic ketoacidosis, chronic kidney disease caused by other diseases, such as nephritis, presence of liver disease, coronary heart disease, or cerebrovascular disease, on systemic corticosteroid treatment, and pregnant or lactati -Abstract Truncated-
endocrinology & metabolism